Explore how updated KDIGO IgAN guidelines, earlier biopsy driven risk stratification, and new targeted therapies (budesonide, sparsentan, complement/APRIL inhibitors) are reshaping long term outcomes.
Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results